ROCO
6496
Market cap40mUSD
Jun 11, Last price
25.60TWD
1D
0.59%
1Q
-13.22%
Jan 2017
-59.37%
IPO
-62.63%
Name
Excelsior Biopharma Inc
Chart & Performance
P/E
—
P/S
1.39
EPS
—
Div Yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
4.46%
Revenues
862m
+11.71%
Net income
-99m
L+8.45%
CFO
-100m
L-25.94%
Profile
Excelsior Biopharma Inc. develops and sells pharmaceutical products in Taiwan, China, and internationally. It offers prescription drugs, over-the-counter drugs, medical devices, healthcare food products, medical supplies, and other products. The company provides its products for the therapeutic areas, such as pediatrics, gastroenterology, neurology, cardiology, dermatology, medical toxicology, dentistry, obstetrics, oncology, hematology, and otorhinolaryngology, as well as infectious diseases. It also offers test kits under the Actim name to detect influenza virus, fecal occult blood, acute pancreatitis, preterm or full-week delivery, and early water breaking. In addition, the company provides toothpaste, and mouth wash and gel products under the Oral7 name; and food and medical beauty maintenance products. Further, it imports and exports active pharmaceutical ingredients; and engages in the research of technologies, and pharmaceutical technologies transfer and cooperative development and improvement activities. The company was formerly known as Excelsior Enterprise Co., Ltd. and changed its name to Excelsior Biopharma Inc. in June 2003. Excelsior Biopharma Inc. was incorporated in 1988 and is headquartered in Taipei, Taiwan.
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | ||||||
Revenues | 861,911 11.71% | 771,562 14.86% | 671,763 -49.81% | |||
Cost of revenue | 940,638 | 851,714 | 704,723 | |||
Unusual Expense (Income) | ||||||
NOPBT | (78,727) | (80,152) | (32,960) | |||
NOPBT Margin | ||||||
Operating Taxes | 11,318 | 9,060 | 7,764 | |||
Tax Rate | ||||||
NOPAT | (90,045) | (89,212) | (40,724) | |||
Net income | (98,705) 8.45% | (91,011) 169.61% | (33,757) 115.71% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | ||||||
BB yield | ||||||
| Debt | ||||||
Debt current | 82,911 | 77,155 | 332,792 | |||
Long-term debt | 656,165 | 654,471 | 96,831 | |||
Deferred revenue | ||||||
Other long-term liabilities | 5,546 | 6,340 | 5,854 | |||
Net debt | 402,600 | 73,524 | (535,094) | |||
| Cash flow | ||||||
Cash from operating activities | (99,797) | (134,750) | 5,486 | |||
CAPEX | (257,150) | (35,657) | (7,783) | |||
Cash from investing activities | (307,033) | 146,618 | (199,244) | |||
Cash from financing activities | 56,992 | (317,226) | (13,728) | |||
FCF | (130,766) | (493,638) | (5,436) | |||
| Balance | ||||||
Cash | 251,525 | 589,918 | 1,106,463 | |||
Long term investments | 84,951 | 68,184 | (141,746) | |||
Excess cash | 293,380 | 619,524 | 931,129 | |||
Stockholders' equity | 565,336 | 876,682 | 753,261 | |||
Invested Capital | 1,142,102 | 868,675 | 831,943 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 46,465 | 45,916 | 47,507 | |||
Price | 29.95 3.81% | 28.85 3.78% | 27.80 -4.96% | |||
Market cap | 1,391,614 5.05% | 1,324,677 0.30% | 1,320,695 -2.92% | |||
EV | 1,794,214 | 1,398,201 | 785,601 | |||
EBITDA | (7,767) | (33,937) | (6,900) | |||
EV/EBITDA | ||||||
Interest | 8,022 | 6,367 | 4,346 | |||
Interest/NOPBT | ||||||